表紙
市場調查報告書
商品編碼
1017640

原發性免疫缺陷症 (PID) (泌尿生殖系統疾病):開發中藥物,2021年

Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 143 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

原發性免疫缺陷症 (PID)被定義為免疫系統減弱,其特徵是更容易出現健康問題,例如反复感染的發展。主要體徵和症狀是胃腸道問題,例​​如血液感染、肺炎、支氣管炎、鼻竇感染、耳部感染、腦膜炎或皮膚感染、痙攣、食慾不振、噁心、腹瀉。

本報告提供世界各國的原發性免疫缺陷症 (PID) 治療用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

目錄

  • 簡介
  • 原發性免疫缺陷症 (PID):概要
  • 原發性免疫缺陷症 (PID):治療藥的開發
  • 原發性免疫缺陷症 (PID):治療藥的評估
  • 原發性免疫缺陷症 (PID):開發治療藥的企業
  • 原發性免疫缺陷症 (PID):藥物簡介
  • 原發性免疫缺陷症 (PID):開發暫停的計劃
  • 原發性免疫缺陷症 (PID):開發中止的產品
  • 原發性免疫缺陷症 (PID):產品開發的里程碑
  • 附錄
目錄
Product Code: GMDHC12841IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 12, 3, 10 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 9, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Primary Immune Deficiency (PID) - Overview
  • Primary Immune Deficiency (PID) - Therapeutics Development
  • Primary Immune Deficiency (PID) - Therapeutics Assessment
  • Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
  • Primary Immune Deficiency (PID) - Drug Profiles
  • Primary Immune Deficiency (PID) - Dormant Projects
  • Primary Immune Deficiency (PID) - Discontinued Products
  • Primary Immune Deficiency (PID) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Primary Immune Deficiency (PID), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, 2021
  • Primary Immune Deficiency (PID) - Pipeline by Biotest AG, 2021
  • Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, 2021
  • Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, 2021
  • Primary Immune Deficiency (PID) - Pipeline by CSL Ltd, 2021
  • Primary Immune Deficiency (PID) - Pipeline by EmendoBio Inc, 2021
  • Primary Immune Deficiency (PID) - Pipeline by Enzyvant Sciences Ltd, 2021
  • Primary Immune Deficiency (PID) - Dormant Projects, 2021
  • Primary Immune Deficiency (PID) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Primary Immune Deficiency (PID), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021